Exactration, LLC
USPTO PatentsView assignee record - 6 granted patents across 4 technology areas, recorded in grant years 2016–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: B01D (Separation).
The verdict
According to USPTO PatentsView, Exactration ranks #40,128 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 4 technology areas.
- #40,128
- of 49,997 US assignees by volume
- 6th percentile
- by Innovation Score (19.6/100)
- 9.7
- avg claims per patent
- -80%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R40128 · US Corporation #40,128 · 6 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-LOW · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 6 grants
- LOWER-Q #40,128/49,997
- PHOTO-FINISH Evox Therapeutics
- CPC-NARROW B01D · 4 areas
- INNOV-LOW 19.6/100
- CLAIMS-PAR 9.7 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -80% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Evox Therapeutics Ltd (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Exactration’s 19.6 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Exactration
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Exactration · this assignee 20
Exactration · this assignee
20 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Exactration's Innovation Score is 19.6/100 (6th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Exactration?
Each dot is one of Exactration’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Exactration’s own 9.7 claims/patent is at or below the 16.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Exactration's grants concentrate
Exactration, LLC is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under B01D (Separation). Peak complete grant year is 2019 (2 grants) versus a trough of 1 in 2016. By volume, Exactration sits between Evox Therapeutics Ltd and Exeltis USA, Inc..
Who files at Exactration's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Evox Therapeutics
Evox Therapeutics Ltd
6 patents
- Exb Asset Managem…
ExB Asset Management GmbH
6 patents
- Exq
ExQ, LLC
6 patents
- Exacttarget
ExactTarget, Inc.
6 patents
- Exagan
Exagan
6 patents
- Exalt Wireless
Exalt Wireless, Inc.
6 patents
- Exaptive
Exaptive, Inc.
6 patents
- Exeltis USA
Exeltis USA, Inc.
6 patents
- Exactration ◀
Exactration, LLC
6 patents
What this shows Exactration holds 6 patents at rank #40,127, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Exactration
By rank, the assignees closest to #40,127 in granted patent volume.
Leaders in B01D (Separation)
Other assignees with the most granted patents in Exactration's primary technology class.
Exactration's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
20 6th percentile higher than 6% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 16.7% |
| 2017 | 1 | 16.7% |
| 2018 | 1 | 16.7% |
| 2019 | 2 | 33.3% |
| 2020 | 1 | 16.7% |
Which technologies does Exactration, LLC patent most?
Top 4 of 4 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Exactration, LLC's patent record in context - here's where to go next.
- Exactration, LLC's lead technology class is B01D (Separation), 100% of its portfolio - see every assignee active in that class. Explore B01D
- Ranked #40,128 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Exactration, LLC against Evox Therapeutics Ltd, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 19.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.